ZEG.F AstraZeneca PLC

Healthcare Pharmaceuticals Frankfurt Exchange
166.20 EUR
Close of Nov 13, 2026
133.09 177.31
Market cap
EUR 258B
P/E
27.3x
P/B
5.59x
ROE
22.4%
Dividend yield
1.66%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ZEG.F undervalued?

Graham number
Price166.20
Graham value63.85
Premium160.3%

ZEG.F trades 160.3% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

AstraZeneca PLC fundamental analysis

No fundamental analysis for AstraZeneca PLC yet.

AstraZeneca PLC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/…

Full company profile